The clinical activity of decitabine (5-aza-2-deoxycytidine, DAC), a hypomethylating agent, has been demonstrated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. However, secondary resistance to this agent often occurs during treatment and leads to treatment failure. It is important to clarify the mechanisms underlying the resistance for improving the efficacy. In this study, by gradually increasing concentration after a continuous induction of DAC, we established the DAC-resistant K562 cell line (K562/DAC) from its parental cell line K562. The proliferation and survival rate of K562/DAC was significantly increased, whereas the apoptosis rate was remarkably decreased than that of K562 after DAC treatment. In K562/ DAC, a total of 108 genes were upregulated and 118 genes were downregulated by RNA-Seq. In addition, we also observed aberrant expression of DDX43/H19/miR-186 axis (increased DDX43/H19 and decreased miR-186) in K562/DAC cells. Ectopic expression of DDX43 in parental K562 cells rendered cells resistant to the DAC. Taken together, we successfully established DAC-resistant K562 cell line which can serve as a good model for investigating DAC resistance mechanisms, and DDX43/H19/miR-186 may be involved in DAC resistance in K562.
| INTRODUC TI ON
DNA methylation is a major contributor to epigenetics involved in carcinogenesis especially in leukemogenesis. The balance is needed to be precisely maintained between DNA hypermethylation and hypomethylation, and dysregulation of the balance may give rise to human diseases. 1 Abnormal DNA methylation changes, associated with DNA methyltransferases (DNMTs), are frequently observed in leukemia and supposedly contribute to disease occurrence and progression. 2, 3 Therapy targeting DNA methylation modifiers has been regarded as a success in the treatment of hematopoietic malignancies. 4, 5 Gene silencing caused by DNA hypermethylation can be reversed pharmacologically by prototypical DNMT inhibitors decitabine (5-aza-2-deoxycytidine, DAC) and 5-azacytidine (AZA), which have been recommended as one of the primary treatments for older acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. [6] [7] [8] The DAC is transported into the cell and then phosphorylated by deoxycytidine kinase (DCK) to the active metabolite 5-aza-dCTP, which incorporates into DNA during DNA replication to form a covalent complex with DNMTs, thereby inhibiting their activities followed by a reduction of DNA methylation, and consequently inducing antileukemia effects. 9 However, increasing clinical studies have found that resistance to such drug can develop during treatment and lead to treatment failure. Drug resistance was the major clinical obstacle to successful treatment of leukemia patients compared to patients with relatively sensitive cells. The clinical outcome of patients after failure with hypomethylating therapy was poor. 10, 11 Insufficient incorporation into DNA was suggested to explain in vitro DAC resistance. 12 It was reported that DNMT3b was upregulated in hypomethylating agent-resistance cell lines. 13 Also, high cytidine deaminase (CDA)/DCK ratio could be a mechanism of primary resistance to DAC in some patients.
14 Nevertheless, the detailed mechanisms leading to DAC resistance still remains obscure. In this study, we induced K562 cell line for long periods of time using DAC to obtain the DAC-resistant K562 cell line and investigated the potential mechanisms of DAC resistance. 
| MATERIAL S AND ME THODS

| Morphology and measurement of drug sensitivity
An inverted light microscope (Nikon) and Wright-Giemsa's compound stain were used to observe K562 and K562/DAC cells during the exponential phase. The nuclear to cytoplasm ratio of the cells was measured, which was the ratio of the diameter of the nucleus to the thickness of the cytoplasm on both sides. Each experiment was repeated three times. IC50 value of DAC was analyzed by the method of probit analysis in SPSS21.0 (SPSS Inc, USA). 
| Cell survival and proliferation assays
| Cell apoptosis
To study cell apoptosis, cells were treated in 25 cm 2 tissue culture flasks without FBS. Then cell apoptosis was evaluated with
Annexin-V-FITC and propidium iodide (PI) double staining using an Annexin V apoptosis detection Kit (556547, Annexin V-FITC Apoptosis Detection Kit I; BD, San Jose, CA, USA) according to the manufacturer's instructions, followed by flow cytometry analysis.
| RNA-Seq analysis
Total RNA was extracted from the cell samples by Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. RNA was subjected to RNA-Seq analysis by Beijing
BerryGenomics Institute, China.
| RQ-PCR
cDNA was reverse transcribed from the RNA. Real-time quantitative PCR (RQ-PCR) was conducted to evaluate the mRNA and miRNA expression levels in the DAC resistant cells as previously described using the primer sets (Table S1 ). 
| Statistical analysis
All experiments were performed in triplicate (n ≥ 3) and the data were presented as mean ± SD. The Student's t test for independent samples was applied to define differences in the experiments. The differences of results were determined statistically significant if P was less than 0.05.
| RE SULTS
| Establishment of DAC-resistant cell line
Morphology differences between K562 and K562/DAC cells were surveyed using an inverted light microscope and Wright-Giemsa's compound staining, and the results were shown in Figure 1A . K562 cells were homogeneous, yet K562/DAC cells were more irregular with little atypia under the light microscope. Wright-Giemsa's compound staining showed that K562/DAC nucleus was more concentrated and the ratio of nucleus to cytoplasm became smaller compared with K562.
The IC50 value for DAC was 0.26 ± 0.02 μmol/L in K562 and 3.16 ± 0.02 μmol/L in K562/DAC (12-fold increase compared to the parental cell line) (P < 0.05) ( Figure 1B ).
To further explore biological property of K562/DAC cells, we found that after treatment with DAC, K562/DAC cells had significantly higher proliferation and survival rates and lower apoptosis rate as compared to K562 cells ( Figure 1C-E) . Meanwhile, the ratio of G0/G1 phase in K562/DAC increased ( Figure 1F ).
| Gene expression alterations identified in K562/DAC cells
To recognize genes associated with DAC resistance, the candidate genes differentially expressed in K562 and K562/DAC cells were identified. RNA-Seq analysis was used to screen the candidates (Figure 2A, Figure S1 ). Figure 2B ). We also performed gene ontology (GO) enrichment analysis to classify differential genes into the categories of cellular component, molecular function and biological process, including extracellular space, protein binding and system development ( Figure 2C ). To gain deeper understanding the roles of these differentially expressed genes in K562/DAC, we further carried out KEGG pathway enrichment analysis. It was found that these genes were mostly enriched in hematopoietic cell lineage, NF-kappa B signaling pathway and many other pathways ( Figure 2D ).
| The role of DDX43/H19/miR-186 in DAC resistance
Our previous study had reported that overexpression of DDX43 in K562 cell line upregulated H19 through demethylation. 20 Also, miR-186 was found to target DDX43, and miR-186 was downregulated in DDX43-transfected cells. 20 Here, the density of H19 and DDX43 methylation was greatly decreased in K562/DAC cells ( Figure 3A and B).
To further confirm the role of DDX43 on the sensitivity of could reduce sensitivity to DAC ( Figure 3E ).
| D ISCUSS I ON
The clinical outcome of patients after treatment failure with the DNA methylation inhibitors is poor in the clinics. ) and its control (K562-NC) were tested. IC50 value increased in K562-DDX43. E, The proliferation of K562-DDX43 was higher than that of control. *P < 0.05, **P < 0.01, compared with control. Error bars indicate SD (n = 3) DAC cells. The DNA methylation inhibitors have no specificity to particular regions due to its extensive demethylation. 24 In conclusion, a good in vitro model was successfully established, which can be used for elucidating the molecular mechanisms related to DAC resistance, and DDX43/H19/miR-186 axis may be associated with DAC resistance. 
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